Rybelsus (semaglutide oral) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 0 Diseases   24 Trials   24 Trials   921 News 


«12...89101112131415161718...1920»
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    [VIRTUAL] Effect of probenecid and cyclosporin on the pharmacokinetics of SNAC in healthy subjects (Rome Hall) -  Jul 13, 2021 - Abstract #EASD2021EASD_796;    
    P1
    These data suggest that patients spent more time in glycaemic control during treatment with oral semaglutide than with empagliflozin. Once-daily oral semaglutide can be dosed with cyclosporin and probenecid with no clinically relevant effects on exposure of SNAC or SNAC metabolites, and with no unexpected safety findings.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    [VIRTUAL] Glycaemic variability of oral semaglutide vs empagliflozin: a post-hoc analysis of PIONEER 2 (Rome Hall) -  Jul 13, 2021 - Abstract #EASD2021EASD_462;    
    P3
    Therefore, we have assessed the change in glycaemic variability and its possible relationship with HbA1c in a 52-week randomised, open-label trial (PIONEER 2) comparing oral semaglutide with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes uncontrolled on metformin.Materials and The seven-point self-measured blood glucose profile (7-point SMBG) was assessed at baseline and at weeks 26 and 52 in the PIONEER 2 trial. Oral semaglutide significantly reduces glycaemic variability, as assessed by the SD of the 7-point SMBG, compared with empagliflozin, and most of this effect was not explained by an indirect effect of HbA1c.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Clinical, Journal:  Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. (Pubmed Central) -  Jul 7, 2021   
    P1
    Several treatment-related characteristics, including route, frequency, and complexity of the treatment play a role in patients' preferences for T2DM treatments and should be considered during treatment selection. After 12 weeks' treatment, ad libitum energy intake was lower with oral semaglutide versus placebo, resulting in reduced body fat mass, and was associated with increased satiety and fullness after a fat-rich breakfast, and improved eating control.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. (Pubmed Central) -  Jul 2, 2021   
    In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the "established CV disease" (CVD) and "CV risk factor" subgroups...After re-categorization, the risk of MACE was significantly lower with semaglutide versus placebo in the established CVD subgroup (hazard ratio [HR], 95% confidence interval [CI]: 0.74 [0.59, 0.92]) and non-significantly lower in the CV risk factor subgroup (HR, 95% CI: 0.84 [0.55, 1.28]) (P-interaction=0.60). These results suggest that the CV effects of semaglutide may extend to patients with T2D across the CV risk continuum.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal, HEOR:  Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. (Pubmed Central) -  Jun 29, 2021   
    Under the assumption that the annual cost of semaglutide is equal to that of OD empagliflozin, OW semaglutide was superior to OD empagliflozin due to its higher quality adjusted life years and lower total costs...Ultimately, the cost-utility results with annual costs of semaglutide of $877.43 and $667.04 were robust to probabilistic sensitivity analysis and scenario analysis. In conclusion, the annual cost of semaglutide appears to be appropriate between $667.04 and $877.43 for T2D patients in China.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Retrospective data, Review, Journal:  Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. (Pubmed Central) -  Jun 28, 2021   
    Nevertheless, it is associated with increased incidence of gastrointestinal adverse events. Further research is needed to clarify its long-term safety and comparative effectiveness against other antidiabetic agents.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    [VIRTUAL] Coming soon: new drugs for treatment of youth with type 2 diabetes0 () -  Jun 9, 2021 - Abstract #ESPE2021ESPE_31;    
    Metformin was the first and only drug approved in 1999 for use in youth with type 2 diabetes (T2D) based on a small, randomized clinical trial...However, formation of the Pediatric Diabetes Consortium (PDC) of leading pediatric diabetes treatment centers in the US was an important turning point, since a primary aim of the PDC is to improve the care of adolescents with T2D by making drugs with proven effectiveness in adults available to youth with T2D. The PDC has already accomplished its current primary goal by participation in the following studies: Exenatide by once weekly injection (approved) Oral dapagliflozin (in analysis of study outcomes) Phase III dapagliflozin and saxagliptin vs placebo study (nearing completion of randomization) Dinamo Phase III empagliflozin and linagliptin vs placebo (nearing completion of enrollment) Dinamo Mono study (in early recruitment phase) Liraglutide by daily injection (approved) Oral Semaglutide (in early recruitment phase) Phase III Alogliptin versus Placebo Study (nearing completion) We strongly believe that the results of these and future randomized clinical trials will transform the care of youth with type 2 diabetes in the future.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal:  Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE. (Pubmed Central) -  Jun 8, 2021   
    Since 2008, the data from various cardiovascular outcome trials have been reported, including SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), TECOS (sitagliptin), CARMELINA (linagliptin), CAROLINA (linagliptin), ELIXA (lixisenatide), LEADER (liraglutide), EXSCEL (exenatide once-weekly), SUSTAIN-6 (injectable semaglutide), HARMONY Outcomes (albiglutide), REWIND (dulaglutide), PIONEER-6 (oral semaglutide), EMPA-REG OUTCOME (empagliflozin), the CANVAS Program (canagliflozin) and DECLARE-TIMI 53 (dapagliflozin)...In this review, we aim to highlight the renal outcome data from the cardiovascular outcome trials and CREDENCE trials and understand the differences between their results. The post CREDENCE era would appear to reinforce the position of sodium-glucose co-transporter-2 inhibitors as drugs providing cardiorenal protection, in addition to their anti-glycaemic effects.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
    Journal:  Nasal Absorption Enhancement of Protein Drugs Independent to Their Chemical Properties in the Presence of Hyaluronic Acid Modified with Tetraglycine-L-octaarginine. (Pubmed Central) -  Jun 3, 2021   
    The studies also revealed that the absorption-enhancing ability of D-octaarginine-linked PNVA-co-AA for exendin-4 was statistically equivalent to that of sodium salcaprozate (SNAC), which is an absorption enhancer formulated in tablets of semaglutide approved recently as an orally available GLP-1 analogue...1.0 kDa, pI: 8.3) and lixisenatide (Mw: ca...It appeared that pI hardly ever influenced absorption-enhancing abilities of both enhancers. Results indicated that our polysaccharide derivative would be a promising absorption enhancer which delivers biologics applied on the nasal mucosa into systemic circulation and was of greater advantage than SNAC for enhancing nasal absorption of protein drugs with a larger Mw.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Trial completion:  A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times (clinicaltrials.gov) -  Jun 2, 2021   
    P1,  N=156, Completed, 
    Results indicated that our polysaccharide derivative would be a promising absorption enhancer which delivers biologics applied on the nasal mucosa into systemic circulation and was of greater advantage than SNAC for enhancing nasal absorption of protein drugs with a larger Mw. Active, not recruiting --> Completed
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    [VIRTUAL] Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence () -  May 29, 2021 - Abstract #ADA2021ADA_1039;    
    P3
    As the first oral GLP-1 receptor agonist (GLP-1RA), oral semaglutide (sema) may facilitate increased access to the benefits of GLP-1RA therapy in broader care settings...Importantly, 75% of pts restarted oral sema after the first AE-related treatment discontinuation. These data highlight the role of treatment pauses, flexibility, and education in mitigating potential AEs to support treatment persistence on GLP-1RAs.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Review, Journal:  Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist. (Pubmed Central) -  May 25, 2021   
    The use of this medication has been associated with glycosylated hemoglobin lowering similar to that with the injectable medication in its same class. Semaglutide was also showed some potential in preventing cardiovascular events as well as increasing weight loss.